Netarsudil opthalmis solution (Rhopressa, Aerie Pharmaceuticals), is approved by the FDA for treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
FDA approved Onzetra Xsail (Avanir Pharmaceuticals Inc.)— a fast-acting, low-dose sumatriptan dry powder formulation for the acute treatment of migraine with or without aura in adults.
Glycopyrrolate bromide is a quick-onset long-acting muscarinic antagonist bronchodilator with FDA approval for use as maintenance treatment of COPD. Seebri Neohaler is approved for use at a dose of 15.6 ug inhaled twice daily.
There is a growing group of LAMA/LABA combination therapies in development. Investigations into the risks and benefits of LAMA/LABA therapy have demonstrated benefits.
FDA has approved mepolizumab for adjunctive maintenance treatment of severe asthma in patients 12 years of age and older with markers of eosinophilic asthma.
